Positive results of selinexor, bortezomib, and dexamethasone in myeloma patients who have received one to three prior lines of therapy

  New data of the phase 3 Boston clinical trial were presented at the American Society of Clinical Oncology (ASCO) Annual Meeting held virtually from 29 to 31 May 2020. This study evaluates weekly selinexor, bortezomib, and dexamethasone (SVd) versus twice weekly bortezomib and dexamethasone (Vd) in myeloma patients who have received one to three prior lines of therapy.

EHA 2020 – Subcutaneous daratumumab shows improved clinical outcomes in AL amyloidosis

  New data of the ANDROMEDA clinical trial has been presented today in the late breaking session at the 25th European Hematology Association (EHA) Annual Congress which is happening virtual from 11 to 21 June. This study evaluates subcutaneous (SC) daratumumab in combination with cyclophosphamide, bortezomib, and dexamethasone (D-CyBorD) compared to CyBorD alone in newly diagnosed patients with AL amyloidosis.

European Commission grants Marketing Authorisation for subcutaneous daratumumab for all approved intravenous daratumumab indications

  The European Commission (EC) has granted marketing authorisation for daratumumab (Darzalex®) subcutaneous (SC) formulation for the treatment of adult myeloma patients. Daratumumab SC is administered as a fixed dose, which significantly reduces treatment time, from hours to approximately three to five minutes, when compared to daratumumab intravenous (IV) formulation.

ASCO 2020 – CAR-T cell therapy highlights in myeloma

  CAR-T cell therapy is one of the most promising treatments in a number of types of cancer. In myeloma, very promising results were presented during the American Society of Clinical Oncology (ASCO) Annual Meeting. Dr Hermann Einsele, Director of the Department of Internal Medicine II at the Würzburg University Hospital, summarises for Myeloma Patients Europe (MPE) the most important CAR-T cells updates in myeloma at ASCO 2020.

European Commission approves isatuximab for relapsed and refractory myeloma patients

  The European Commission (EC) has approved isatuximab (Sarclisa®) in combination with pomalidomide and dexamethasone (pom-dex) for the treatment of adult patients with relapsed and refractory myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy.

ASCO 2020 myeloma highlights

  The largest, and one of the most important, oncology meetings in the calendar year, the American Society of Clinical Oncology (ASCO) annual scientific meeting, was held from 29 to 31 May. Myeloma Patients Europe attended this virtual meeting and interviewed Dr Katja Weisel, University Medical Center Hamburg-Eppendorf in Germany, to summarise the most important myeloma highlights presented at ASCO20.

Relevant myeloma and AL amyloidosis sessions at ASCO20 Virtual Scientific Program

  From 29 to 31 May, the American Society of Clinical Oncology (ASCO) will hold its annual scientific meeting. This is the largest, and one of the most important, oncology meetings in the calendar year. For the first time, ASCO20 will be held virtually adapting its programme and sessions to the COVID-19 situation. The programme will still feature over 250 oral abstract presentations and 2,500 poster presentations in 24 disease-based and speciality tracks. All presentations will…

FDA Refusal to File letter for Idecabtagene Vicleucel (ide-cel, bb2121) for the treatment of myeloma patients

  Bristol Myers Squibb (BMS) and bluebird bio, Inc have announced that the companies received a Refusal to File letter from the U.S. Food and Drug Administration (FDA) regarding the Biologics License Application (BLA) for idecabtagene vicleucel (ide-cel; bb2121) for patients with heavily pre-treated relapsed and refractory myeloma, which was submitted in March 2020.